Literature DB >> 11161380

The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis.

S Sivagnanasundaram1, I Islam, I Talbot, F Drummond, J R Walters, Y H Edwards.   

Abstract

Accumulation of mutations in tumour suppressor genes and oncogenes has been proposed to underlie the initiation and progression of sporadic colorectal cancer (CRC). Evidence is accumulating to suggest that the caudal homeobox gene CDX2 is implicated in the pathogenesis of CRC. The CDX2 transcription factor is expressed in intestinal epithelium and is markedly down-regulated in colon tumours. Furthermore, Cdx2 heterozygous null mice develop multiple intestinal tumours. In this present study, we have investigated CDX2 as a potential candidate gene for sporadic CRC by a thorough search of all exons and exon/intron boundaries for DNA polymorphisms and rare variants in a panel of CRC tumours. 6 polymorphisms were identified and the haplotypes determined. In addition two rare variants were found, one of which was only identified in DNA from a CRC case. Loss of heterozygosity was observed in 3 out of 28 informative CRC cases. A possible association between particular haplotypes and tumour progression was also suggested by the data. In addition a preliminary analysis of the relative expression of CDX2 alleles in tumour/normal tissue suggested some variation in the levels, however further analysis is required before any conclusions can be drawn. While CDX2 mutations predisposing to sporadic CRC have not been identified, this study has established that loss of CDX2 contributes towards the progression of some sporadic CRC tumours. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161380      PMCID: PMC2363702          DOI: 10.1054/bjoc.2000.1544

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex.

Authors:  M S German; J Wang; R B Chadwick; W J Rutter
Journal:  Genes Dev       Date:  1992-11       Impact factor: 11.361

2.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue.

Authors:  S E Goelz; S R Hamilton; B Vogelstein
Journal:  Biochem Biophys Res Commun       Date:  1985-07-16       Impact factor: 3.575

3.  Homeobox gene expression in the intestinal epithelium of adult mice.

Authors:  R James; J Kazenwadel
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

4.  Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.

Authors:  C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

5.  Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.

Authors:  R A Lothe; T Fossli; H E Danielsen; A E Stenwig; J M Nesland; B Gallie; A L Børresen
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

6.  Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas.

Authors:  S Cottrell; D Bicknell; L Kaklamanis; W F Bodmer
Journal:  Lancet       Date:  1992-09-12       Impact factor: 79.321

7.  Identification and characterization of the familial adenomatous polyposis coli gene.

Authors:  J Groden; A Thliveris; W Samowitz; M Carlson; L Gelbert; H Albertsen; G Joslyn; J Stevens; L Spirio; M Robertson
Journal:  Cell       Date:  1991-08-09       Impact factor: 41.582

8.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.

Authors:  I Nishisho; Y Nakamura; Y Miyoshi; Y Miki; H Ando; A Horii; K Koyama; J Utsunomiya; S Baba; P Hedge
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

9.  Expression from the proximal promoter of the carbonic anhydrase 1 gene as a marker for differentiation in colon epithelia.

Authors:  J Sowden; S Leigh; I Talbot; J Delhanty; Y Edwards
Journal:  Differentiation       Date:  1993-06       Impact factor: 3.880

10.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

View more
  6 in total

1.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  No association between the polymorphisms in CDX2 coding regions and colorectal cancer in Chinese.

Authors:  Xiaoping Xia; Enping Xu; Sheng Quan; Qiong Huang; Maode Lai
Journal:  Mol Cell Biochem       Date:  2009-05-07       Impact factor: 3.396

Review 3.  Molecular mechanisms of Barrett's esophagus.

Authors:  Hao Chen; Yu Fang; Whitney Tevebaugh; Roy C Orlando; Nicholas J Shaheen; Xiaoxin Chen
Journal:  Dig Dis Sci       Date:  2011-10-08       Impact factor: 3.199

Review 4.  Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.

Authors:  Peng Li; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2010-08-11       Impact factor: 4.742

5.  The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development.

Authors:  C Bonhomme; I Duluc; E Martin; K Chawengsaksophak; M-P Chenard; M Kedinger; F Beck; J-N Freund; C Domon-Dell
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

6.  Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Ellen Freed; Natsumi Irahara; Juliet Philips; Jeffrey A Meyerhardt; Jason L Hornick; Ramesh A Shivdasani; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.